These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35026375)

  • 1. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial.
    Bosaeed M; Alharbi A; Mahmoud E; Alrehily S; Bahlaq M; Gaifer Z; Alturkistani H; Alhagan K; Alshahrani S; Tolbah A; Musattat A; Alanazi M; Jaha R; Sultana K; Alqahtani H; Al Aamer K; Jaser S; Alsaedy A; Ahmad A; Abalkhail M; AlJohani S; Al Jeraisy M; Almaziad S; Albaalharith N; Alabdulkareem K; Alshowair A; Alharbi NK; Alrabiah F; Alshamrani M; Aldibasi O; Alaskar A
    Clin Microbiol Infect; 2022 Apr; 28(4):602-608. PubMed ID: 35026375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.
    Bosaeed M; Alharbi A; Hussein M; Abalkhail M; Sultana K; Musattat A; Alqahtani H; Alshamrani M; Mahmoud E; Alothman A; Alsaedy A; Aldibasi O; Alhagan K; Asiri AM; AlJohani S; Al-Jeraisy M; Alaskar A
    BMJ Open; 2021 Apr; 11(4):e047495. PubMed ID: 33853806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
    Holubar M; Subramanian A; Purington N; Hedlin H; Bunning B; Walter KS; Bonilla H; Boumis A; Chen M; Clinton K; Dewhurst L; Epstein C; Jagannathan P; Kaszynski RH; Panu L; Parsonnet J; Ponder EL; Quintero O; Sefton E; Singh U; Soberanis L; Truong H; Andrews JR; Desai M; Khosla C; Maldonado Y
    Clin Infect Dis; 2022 Nov; 75(11):1883-1892. PubMed ID: 35446944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).
    Smith T; Hoyo-Vadillo C; Adom AA; Favari-Perozzi L; Gastine S; Dehbi HM; Villegas-Lara B; Mateos E; González YSP; Navarro-Gualito MD; Cruz-Carbajal AS; Cortes-Vazquez MA; Bekker-Méndez C; Aguirre-Alvarado C; Aguirre-Gil G; Delgado-Pastelin L; Owen A; Lowe D; Standing J; Escobedo J
    Trials; 2022 Jul; 23(1):583. PubMed ID: 35869526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19.
    Iwata S; Kobayashi O; Kurashima K; Doi Y; Kunishima H; Shinkai M; Tsushima K; Yamato M; Kano A; Hibino M; Yamatake T; Sakurai T; Ogura T
    J Infect Chemother; 2024 Mar; 30(3):219-227. PubMed ID: 37832822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
    Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
    Lowe DM; Brown LK; Chowdhury K; Davey S; Yee P; Ikeji F; Ndoutoumou A; Shah D; Lennon A; Rai A; Agyeman AA; Checkley A; Longley N; Dehbi HM; Freemantle N; Breuer J; Standing JF;
    PLoS Med; 2022 Oct; 19(10):e1004120. PubMed ID: 36260627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial.
    Golan Y; Campos JAS; Woolson R; Cilla D; Hanabergh R; Gonzales-Rojas Y; Lopez R; Finberg R; Balboni A
    Clin Infect Dis; 2023 Feb; 76(3):e10-e17. PubMed ID: 36065065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.